HBL - Hadasit Bio-Holdings Ltd (HDST.M)
Market Closed
7 Aug, 15:25
TASE TASE Primary 64. 80
ILA 0
0%
5.17M Market Cap
- P/E Ratio
- Div Yield
2,260 Volume
- Eps
64.8 ILA
Previous Close Want to track HDST.M and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
HDST.M closed Friday higher at 64.8 ILA, an increase of 0% from Thursday's close, completing a monthly decrease of -10.6207% or -7.7 ILA. Over the past 12 months, HDST.M stock gained 109.0323%.
HDST.M pays dividends to its shareholders, with the most recent payment made on Feb 14, 2019.
HBL - Hadasit Bio-Holdings Ltd has completed 2 stock splits, with the recent split occurring on Jul 24, 2016.
The company's stock is traded on one exchange.
HBL - Hadasit Bio-Holdings Ltd (HDST.M) FAQ
What is the stock price today?
The current price is 64.80 ILA.
On which exchange is it traded?
HBL - Hadasit Bio-Holdings Ltd is listed on TASE.
What is its stock symbol?
The ticker symbol is HDST.M.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 5.17M.
Has HBL - Hadasit Bio-Holdings Ltd ever had a stock split?
HBL - Hadasit Bio-Holdings Ltd had 2 splits and the recent split was on Jul 24, 2016.
HBL - Hadasit Bio-Holdings Ltd Profile
| Biotechnology Industry | Healthcare Sector | Mr. Yoram Azulai CEO | TASE Exchange | - ISIN |
| IL Country | 2 Employees | 7 Feb 2019 Last Dividend | 24 Jul 2016 Last Split | - IPO Date |
Overview
HBL - Hadasit Bio-Holdings Ltd is a distinguished player in the biotechnology industry, situated in the innovation-rich country of Israel. Since its establishment in 2005, the company has dedicated itself to pushing the boundaries in the biotechnological field, focusing on oncology, regenerative medicine, and inflammatory disease. Operating from its headquarters in Jerusalem, Israel, HBL - Hadasit Bio-Holdings Ltd leverages its expertise to develop cutting-edge biological drugs, making significant strides in the treatment and understanding of various diseases.
Products and Services
- Biological Drugs Development: The core focus of HBL - Hadasit Bio-Holdings Ltd is on the development of innovative biological drugs. This involves harnessing scientific discoveries and advancements to create effective treatments for a multitude of conditions, with a particular emphasis on oncology, regenerative medicine, and inflammatory diseases.
- Plasma RNA Biomarkers for Colorectal Cancer: HBL is at the forefront of diagnostic advancements with its development of plasma RNA biomarkers. These biomarkers are specifically designed for colorectal cancer, offering a groundbreaking approach to early detection and monitoring of the disease. This technological advancement represents a significant leap forward in the fight against one of the most common and deadly forms of cancer.
- ProtAb: Among HBL's innovative products is ProtAb, an immunotherapeutic monoclonal antibody designed for the treatment of autoimmune inflammatory diseases. ProtAb represents an important step forward in the management of these chronic conditions, providing new hope for patients through its unique mechanism of action which targets the underlying causes of inflammation.
Contact Information
Address: Jerusalem Bio-Park
Phone: 972 3 567 0100
Website: https://www.hbl.co.il
